174 related articles for article (PubMed ID: 31471576)
1. The efficacy and heterogeneity of antipsychotic response in schizophrenia: A meta-analysis.
McCutcheon RA; Pillinger T; Mizuno Y; Montgomery A; Pandian H; Vano L; Marques TR; Howes OD
Mol Psychiatry; 2021 Apr; 26(4):1310-1320. PubMed ID: 31471576
[TBL] [Abstract][Full Text] [Related]
2. Heterogeneity and efficacy of antipsychotic treatment for schizophrenia with or without treatment resistance: a meta-analysis.
Mizuno Y; McCutcheon RA; Brugger SP; Howes OD
Neuropsychopharmacology; 2020 Mar; 45(4):622-631. PubMed ID: 31766049
[TBL] [Abstract][Full Text] [Related]
3. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
4. Variability and magnitude of brain glutamate levels in schizophrenia: a meta and mega-analysis.
Merritt K; McCutcheon RA; Aleman A; Ashley S; Beck K; Block W; Bloemen OJN; Borgan F; Boules C; Bustillo JR; Capizzano AA; Coughlin JM; David A; de la Fuente-Sandoval C; Demjaha A; Dempster K; Do KQ; Du F; Falkai P; Galińska-Skok B; Gallinat J; Gasparovic C; Ginestet CE; Goto N; Graff-Guerrero A; Ho BC; Howes O; Jauhar S; Jeon P; Kato T; Kaufmann CA; Kegeles LS; Keshavan MS; Kim SY; King B; Kunugi H; Lauriello J; León-Ortiz P; Liemburg E; Mcilwain ME; Modinos G; Mouchlianitis E; Nakamura J; Nenadic I; Öngür D; Ota M; Palaniyappan L; Pantelis C; Patel T; Plitman E; Posporelis S; Purdon SE; Reichenbach JR; Renshaw PF; Reyes-Madrigal F; Russell BR; Sawa A; Schaefer M; Shungu DC; Smesny S; Stanley JA; Stone J; Szulc A; Taylor R; Thakkar KN; Théberge J; Tibbo PG; van Amelsvoort T; Walecki J; Williamson PC; Wood SJ; Xin L; Yamasue H; McGuire P; Egerton A;
Mol Psychiatry; 2023 May; 28(5):2039-2048. PubMed ID: 36806762
[TBL] [Abstract][Full Text] [Related]
5. Second-generation antipsychotic drugs and short-term mortality: a systematic review and meta-analysis of placebo-controlled randomised controlled trials.
Schneider-Thoma J; Efthimiou O; Huhn M; Krause M; Reichelt L; Röder H; Davis JM; Salanti G; Leucht S
Lancet Psychiatry; 2018 Aug; 5(8):653-663. PubMed ID: 30042077
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme.
Bugarski-Kirola D; Iwata N; Sameljak S; Reid C; Blaettler T; Millar L; Marques TR; Garibaldi G; Kapur S
Lancet Psychiatry; 2016 Dec; 3(12):1115-1128. PubMed ID: 27816567
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia: Systematic Overview and Quality Appraisal of the Meta-analytic Evidence.
Correll CU; Rubio JM; Inczedy-Farkas G; Birnbaum ML; Kane JM; Leucht S
JAMA Psychiatry; 2017 Jul; 74(7):675-684. PubMed ID: 28514486
[TBL] [Abstract][Full Text] [Related]
8. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
9. Modafinil for people with schizophrenia or related disorders.
Ortiz-Orendain J; Covarrubias-Castillo SA; Vazquez-Alvarez AO; Castiello-de Obeso S; Arias Quiñones GE; Seegers M; Colunga-Lozano LE
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD008661. PubMed ID: 31828767
[TBL] [Abstract][Full Text] [Related]
10. The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses.
Haddad PM; Correll CU
Ther Adv Psychopharmacol; 2018 Nov; 8(11):303-318. PubMed ID: 30344997
[TBL] [Abstract][Full Text] [Related]
11. Standard versus reduced dose of antipsychotics for relapse prevention in multi-episode schizophrenia: a systematic review and meta-analysis of randomised controlled trials.
Højlund M; Kemp AF; Haddad PM; Neill JC; Correll CU
Lancet Psychiatry; 2021 Jun; 8(6):471-486. PubMed ID: 34023019
[TBL] [Abstract][Full Text] [Related]
12. Pimozide for schizophrenia or related psychoses.
Mothi M; Sampson S
Cochrane Database Syst Rev; 2013 Nov; (11):CD001949. PubMed ID: 24194433
[TBL] [Abstract][Full Text] [Related]
13. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies.
Furukawa TA; Levine SZ; Tanaka S; Goldberg Y; Samara M; Davis JM; Cipriani A; Leucht S
JAMA Psychiatry; 2015 Jan; 72(1):14-21. PubMed ID: 25372935
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.
Leucht S; Cipriani A; Spineli L; Mavridis D; Orey D; Richter F; Samara M; Barbui C; Engel RR; Geddes JR; Kissling W; Stapf MP; Lässig B; Salanti G; Davis JM
Lancet; 2013 Sep; 382(9896):951-62. PubMed ID: 23810019
[TBL] [Abstract][Full Text] [Related]
15. Reappraising the variability of effects of antipsychotic medication in schizophrenia: a meta-analysis.
McCutcheon RA; Pillinger T; Efthimiou O; Maslej M; Mulsant BH; Young AH; Cipriani A; Howes OD
World Psychiatry; 2022 Jun; 21(2):287-294. PubMed ID: 35524614
[TBL] [Abstract][Full Text] [Related]
16. Response efficacy and heterogeneity of antipsychotic drugs in schizophrenia: Systemic review and meta-analysis.
Zhang X; Tang J; Zhang X; Abdelrahim MEA; Yin Z
Hum Psychopharmacol; 2022 Jan; 37(1):e2808. PubMed ID: 34418150
[TBL] [Abstract][Full Text] [Related]
17. Association of Ketamine With Psychiatric Symptoms and Implications for Its Therapeutic Use and for Understanding Schizophrenia: A Systematic Review and Meta-analysis.
Beck K; Hindley G; Borgan F; Ginestet C; McCutcheon R; Brugger S; Driesen N; Ranganathan M; D'Souza DC; Taylor M; Krystal JH; Howes OD
JAMA Netw Open; 2020 May; 3(5):e204693. PubMed ID: 32437573
[TBL] [Abstract][Full Text] [Related]
18. The magnitude and heterogeneity of antidepressant response in depression: A meta-analysis of over 45,000 patients.
Guo X; McCutcheon RA; Pillinger T; Mizuno Y; Natesan S; Brown K; Howes O
J Affect Disord; 2020 Nov; 276():991-1000. PubMed ID: 32750615
[TBL] [Abstract][Full Text] [Related]
19. Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis.
Smith RC; Leucht S; Davis JM
Psychopharmacology (Berl); 2019 Feb; 236(2):545-559. PubMed ID: 30506237
[TBL] [Abstract][Full Text] [Related]
20. Quetiapine : A Review of its Use in Schizophrenia.
Gunasekara NS; Spencer CM
CNS Drugs; 1998 Apr; 9(4):325-40. PubMed ID: 27521016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
